Table 1 Basic characteristics of PPS patients.
From: Prognostic visualization model for primary pulmonary sarcoma: a SEER-based study
Development training group | Validation group | Overall | χ2 | P | |
|---|---|---|---|---|---|
(N = 118) | (N = 51) | (N = 169) | |||
Age | 0.014 | 0.904 | |||
< 65 | 55 (46.6%) | 25 (49.0%) | 80 (47.3%) | ||
≥ 65 | 63 (53.4%) | 26 (51.0%) | 89 (52.7%) | ||
Sex | 1.152 | 0.283 | |||
Female | 49 (41.5%) | 16 (31.4%) | 65 (38.5%) | ||
Male | 69 (58.5%) | 35 (68.6%) | 104 (61.5%) | ||
Race | 3.917 | 0.141 | |||
Black | 6 (5.1%) | 6 (11.8%) | 12 (7.1%) | ||
Other | 12 (10.2%) | 2 (3.9%) | 14 (8.3%) | ||
White | 100 (84.7%) | 43 (84.3%) | 143 (84.6%) | ||
Marital | 0.203 | 0.653 | |||
Married | 61 (51.7%) | 29 (56.9%) | 90 (53.3%) | ||
Other | 57 (48.3%) | 22 (43.1%) | 79 (46.7%) | ||
Grade | 0.088 | 0.767 | |||
I-II | 20 (16.9%) | 7 (13.7%) | 27 (16.0%) | ||
III-IV | 98 (83.1%) | 44 (86.3%) | 142 (84.0%) | ||
Metastasis | |||||
Lung | < 0.001 | 1.000 | |||
No/Unknown | 105 (89.0%) | 46 (90.2%) | 151 (89.3%) | ||
Yes | 13 (11.0%) | 5 (9.8%) | 18 (10.7%) | ||
Bone | < 0.001 | 0.988 | |||
No/Unknown | 107 (90.7%) | 47 (92.2%) | 154 (91.1%) | ||
Yes | 11 (9.3%) | 4 (7.8%) | 15 (8.9%) | ||
Liver | < 0.001 | 1.000 | |||
No/Unknown | 115 (97.5%) | 49 (96.1%) | 164 (97.0%) | ||
Yes | 3 (2.5%) | 2 (3.9%) | 5 (3.0%) | ||
Brain | 1.162 | 0.281 | |||
No/Unknown | 109 (92.4%) | 50 (98.0%) | 159 (94.1%) | ||
Yes | 9 (7.6%) | 1 (2.0%) | 10 (5.9%) | ||
Surgery | 0.046 | 0.829 | |||
No | 61 (51.7%) | 28 (54.9%) | 89 (52.7%) | ||
Yes | 57 (48.3%) | 23 (45.1%) | 80 (47.3%) | ||
Radiation | 2.971 | 0.085 | |||
No/Unknown | 75 (63.6%) | 40 (78.4%) | 115 (68.0%) | ||
Yes | 43 (36.4%) | 11 (21.6%) | 54 (32.0%) | ||
Chemotherapy | 0.060 | 0.807 | |||
No/Unknown | 78 (66.1%) | 32 (62.7%) | 110 (65.1%) | ||
Yes | 40 (33.9%) | 19 (37.3%) | 59 (34.9%) |
